Application

19881338 · Combination of Antibodies Targeting DLL4/VEGF and CD137 Agonists or Anti-PD1/ Anti-PD-L1 Antibodies for The Treatment of Cancer

Filed 2026-10-01 · Pending The official file ↗ · Art unit · Compass Therapeutics Inc. · BROWNSTEIN HYATT FARBER SCHRECK, LLP

Office actions

first was

RCEs

no appeal

To first action

n/a

to disposition n/a

Statutes raised

0 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.